Loading clinical trials...
Loading clinical trials...
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Conditions
Interventions
Brolucizumab 6 mg
Aflibercept 2 mg
+1 more
Locations
102
United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Mountain View, California, United States
Novartis Investigative Site
Santa Barbara, California, United States
Novartis Investigative Site
Colorado Springs, Colorado, United States
Novartis Investigative Site
Pensacola, Florida, United States
Novartis Investigative Site
St. Petersburg, Florida, United States
Start Date
July 2, 2019
Primary Completion Date
July 26, 2021
Completion Date
July 26, 2021
Last Updated
January 30, 2023
NCT05476926
NCT05520177
NCT06708637
NCT02390245
NCT05127525
NCT02006147
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions